Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

Ana Luísa Caires de Souza, Francisco de Assis Acurcio, Augusto Afonso Guerra Júnior, Renata Cristina Rezende Macedo do Nascimento, Brian Godman, Leonardo Maurício Diniz

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
27 Downloads (Pure)


Dear Editor,

We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients.

However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.
Original languageEnglish
Pages (from-to)561-563
Number of pages3
JournalApplied Health Economics and Health Policy
Issue number5
Early online date14 Aug 2014
Publication statusPublished - 1 Oct 2014


  • insulin glargine
  • Brazil
  • insulin analogues


Dive into the research topics of 'Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"'. Together they form a unique fingerprint.

Cite this